McDonnell, T;
Ioannou, Y;
Rahman, A;
(2014)
PEGylated drugs in rheumatology--why develop them and do they work?
Rheumatology
, 53
(3)
pp. 391-396.
10.1093/rheumatology/ket278.
Preview |
PDF
McDonnell_Rheumatology.pdf Download (132kB) |
Abstract
Lack of efficacy and drug-related adverse effects are important reasons for the discontinuation of treatment in patients with rheumatic diseases. The development of new biologic therapies seeks to address these problems by specifically targeting the pathogenic mechanisms of disease. Most current biologics are proteins (particularly antibodies and enzymes) administered parenterally. It is important to optimize properties such as serum half-life, immunogenicity and solubility. Companies have thus begun to modify the drugs by conjugate chemistry, binding inert molecules such as polyethylene glycol (PEG) to biologic molecules to improve their pharmacodynamic properties. The use of PEG to alter these properties has to be weighed against the negative aspects of PEGylation, such as decreased activity and heterogeneity. This review focuses on the currently available PEGylated drugs used in rheumatological diseases, their efficacy, drawbacks and the current clinical trial evidence supporting their use.
Type: | Article |
---|---|
Title: | PEGylated drugs in rheumatology--why develop them and do they work? |
Open access status: | An open access version is available from UCL Discovery |
DOI: | 10.1093/rheumatology/ket278 |
Publisher version: | http://dx.doi.org/10.1093/rheumatology/ket278 |
Language: | English |
Additional information: | © The Author 2013. Published by Oxford University Press on behalf of the British Society for Rheumatology. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. |
Keywords: | PEGylation, Clinical trials, Gout, Rheumatoid arthritis |
UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Inflammation UCL > Provost and Vice Provost Offices > UCL BEAMS UCL > Provost and Vice Provost Offices > UCL BEAMS > Faculty of Engineering Science UCL > Provost and Vice Provost Offices > UCL BEAMS > Faculty of Engineering Science > Dept of Biochemical Engineering |
URI: | https://discovery.ucl.ac.uk/id/eprint/1403323 |
Archive Staff Only
View Item |